Bioventus (BVS)
Makes orthopedic treatments for knee pain, surgical bone repair, and fracture healing.
$13.62
vs last close+0.31 (+2.33%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 121 | 135 | 129 | 151 | 139 | 154 | 124 | 148 | 139 | 158 | 132 | 153 |
| Cost of revenue | 42 | 49 | 41 | 48 | 45 | 51 | 42 | 47 | 46 | 50 | 42 | 48 |
| Gross profit | 79 | 86 | 88 | 104 | 94 | 103 | 81 | 101 | 93 | 107 | 90 | 106 |
| 76 | 85 | 83 | 135 | 89 | 95 | 76 | 82 | 81 | 86 | 81 | 87 | |
| Research & development | 3 | 3 | 3 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 2 | 3 |
| Selling, general & administrative | 70 | 78 | 79 | 97 | 81 | 87 | 73 | 79 | 78 | 83 | 78 | 83 |
| Other expenses | 4 | 4 | 2 | 34 | 5 | 5 | 0 | 0 | 0 | 0 | 0 | 1 |
| Operating income | 2 | 1 | 5 | −31 | 4 | 8 | 5 | 19 | 12 | 22 | 9 | 19 |
| −11 | −10 | −10 | −10 | −9 | −8 | −8 | −8 | −7 | −8 | −4 | −4 | |
| Interest expense | 10 | 10 | 10 | 10 | 10 | 9 | 8 | 7 | 6 | 5 | 4 | 4 |
| Other non-operating income | 0 | −1 | 0 | 0 | −1 | −1 | 1 | 1 | 1 | 2 | 0 | 0 |
| Income before tax | −8 | −8 | −5 | −42 | −5 | 0 | −3 | 10 | 5 | 14 | 5 | 15 |
| Income tax expense | 1 | −1 | 1 | −7 | 1 | 1 | 0 | 1 | 1 | −3 | 1 | −21 |
| Net income from continuing operations | −9 | −8 | −6 | −34 | −5 | 0 | −3 | 9 | 4 | 17 | 4 | 36 |
| Net income | −7 | −6 | −5 | −26 | −5 | 0 | −3 | 7 | 3 | 15 | 3 | 33 |
| EPS, basic | −$0.12 | −$0.10 | −$0.08 | −$0.37 | −$0.07 | −$0.00 | −$0.04 | $0.11 | $0.05 | $0.22 | $0.05 | $0.49 |
| EPS, diluted | −$0.12 | −$0.10 | −$0.08 | −$0.37 | −$0.07 | −$0.00 | −$0.04 | $0.11 | $0.05 | $0.21 | $0.04 | $0.47 |
| Weighted average shares, basic | 63 | 63 | 63 | 64 | 65 | 65 | 66 | 67 | 67 | 67 | 67 | 68 |
| Weighted average shares, diluted | 63 | 63 | 63 | 64 | 65 | 65 | 66 | 69 | 69 | 69 | 70 | 71 |
| EBITDA | 16 | 14 | 17 | −19 | 17 | 22 | 16 | 30 | 22 | 31 | 20 | 19 |
| Depreciation & amortization | 14 | 12 | 12 | 13 | 12 | 12 | 12 | 12 | 11 | 12 | 11 | 0 |
| EBIT | 2 | 2 | 5 | −32 | 5 | 9 | 4 | 18 | 11 | 19 | 9 | 19 |